39485355|t|Pulmonary Atelectasis After Sedation With Propofol vs Propofol-Ketamine for Magnetic Resonance Imaging in Children: A Randomized Clinical Trial.
39485355|a|Importance: Little is known about the impact of different anesthetic agents used for routine magnetic resonance imaging (MRI) sedation on pulmonary function in children. Objective: To compare the incidence of pulmonary atelectasis after MRI sedation with propofol vs propofol-ketamine. Design, Setting, and Participants: This double-masked randomized clinical trial screened 117 consecutive pediatric patients aged 3 to 12 years with American Society of Anesthesiologists physical status I to II undergoing elective MRI under deep sedation from November 2, 2022, to April 28, 2023, at a tertiary referral center. Four patients met the exclusion criteria, and 5 patients refused to participate. The participants and outcome assessors were masked to the group allocation. Interventions: During the MRI, the propofol group received 0.2 mL/kg of 1% propofol and 2 mL of 0.9% saline followed by a continuous infusion of propofol (200 mug/kg/min) and 0.9% saline (0.04 mL/kg/min). The propofol-ketamine group received 0.2 mL/kg of 0.5% propofol and 1 mg/kg of ketamine followed by a continuous infusion of propofol (100 mug/kg/min) and ketamine (20 mug/kg/min). Main Outcome and Measure: The incidence of atelectasis assessed by lung ultrasonography examination. Results: A total of 107 children (median [IQR] age, 5 [4-6] years; 62 male [57.9%]), with 54 in the propofol group and 53 in the propofol-ketamine group, were analyzed in this study. Notably, 48 (88.9%) and 31 (58.5%) patients had atelectasis in the propofol and propofol-ketamine groups, respectively (relative risk, 0.7; 95% CI, 0.5-0.8; P < .001). The incidence of desaturation and interruption of the MRI due to airway intervention or spontaneous movement did not significantly differ between the groups. The propofol-ketamine group showed a faster emergence time than the propofol group (15 [9-23] vs 25 [22-27] minutes in the propofol-ketamine vs propofol group; median difference in time, 9.0 minutes; 95% CI, 6.0-12.0 minutes; P < .001). No patient was withdrawn from the trial due to adverse effects. Conclusions and Relevance: In this randomized clinical trial, the propofol-ketamine combination reduced sedation-induced atelectasis while allowing for faster emergence compared with propofol alone. Trial Registration: cris.nih.go.kr Identifier: KCT0007699.
39485355	0	21	Pulmonary Atelectasis	Disease	MESH:D001261
39485355	42	50	Propofol	Chemical	MESH:D015742
39485355	54	62	Propofol	Chemical	MESH:D015742
39485355	63	71	Ketamine	Chemical	MESH:D007649
39485355	354	375	pulmonary atelectasis	Disease	MESH:D001261
39485355	400	408	propofol	Chemical	MESH:D015742
39485355	412	420	propofol	Chemical	MESH:D015742
39485355	421	429	ketamine	Chemical	MESH:D007649
39485355	452	464	Participants	Species	9606
39485355	546	554	patients	Species	9606
39485355	763	771	patients	Species	9606
39485355	806	814	patients	Species	9606
39485355	843	855	participants	Species	9606
39485355	950	958	propofol	Chemical	MESH:D015742
39485355	990	998	propofol	Chemical	MESH:D015742
39485355	1060	1068	propofol	Chemical	MESH:D015742
39485355	1124	1132	propofol	Chemical	MESH:D015742
39485355	1133	1141	ketamine	Chemical	MESH:D007649
39485355	1175	1183	propofol	Chemical	MESH:D015742
39485355	1199	1207	ketamine	Chemical	MESH:D007649
39485355	1245	1253	propofol	Chemical	MESH:D015742
39485355	1275	1283	ketamine	Chemical	MESH:D007649
39485355	1344	1355	atelectasis	Disease	MESH:D001261
39485355	1502	1510	propofol	Chemical	MESH:D015742
39485355	1531	1539	propofol	Chemical	MESH:D015742
39485355	1540	1548	ketamine	Chemical	MESH:D007649
39485355	1620	1628	patients	Species	9606
39485355	1633	1644	atelectasis	Disease	MESH:D001261
39485355	1652	1660	propofol	Chemical	MESH:D015742
39485355	1665	1673	propofol	Chemical	MESH:D015742
39485355	1674	1682	ketamine	Chemical	MESH:D007649
39485355	1770	1782	desaturation	Disease	
39485355	1915	1923	propofol	Chemical	MESH:D015742
39485355	1924	1932	ketamine	Chemical	MESH:D007649
39485355	1979	1987	propofol	Chemical	MESH:D015742
39485355	2034	2042	propofol	Chemical	MESH:D015742
39485355	2043	2051	ketamine	Chemical	MESH:D007649
39485355	2055	2063	propofol	Chemical	MESH:D015742
39485355	2151	2158	patient	Species	9606
39485355	2278	2286	propofol	Chemical	MESH:D015742
39485355	2287	2295	ketamine	Chemical	MESH:D007649
39485355	2333	2344	atelectasis	Disease	MESH:D001261
39485355	2395	2403	propofol	Chemical	MESH:D015742
39485355	Cotreatment	MESH:D007649	MESH:D015742
39485355	Positive_Correlation	MESH:D007649	MESH:D001261
39485355	Positive_Correlation	MESH:D015742	MESH:D001261

